Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 21, 2015 10:47 AM ET

Healthcare Providers and Services

Company Overview of Janssen Inc.

Company Overview

Janssen Inc. distributes healthcare products. The company offers products for mental wellness, anemia and fatigue, kidney disease, women’s health, wound healing, Alzheimer disease, eldercare, psychiatry, neurology, dementia, attention deficit hyperactivity disorder, immunology, pain management, gastroenterology, infectious diseases, and urology. It also offers oral medications for the treatment of HIV infection in combination with other antiretroviral agents. Janssen Inc. was formerly known as Janssen-Ortho Inc. The company was founded in 1941 and is based in Toronto, Canada with a division office in Montreal. Janssen Inc. operates as a subsidiary of Johnson & Johnson.

19 Green Belt Drive

Toronto, ON M3C 1L9

Canada

Founded in 1941

Phone:

416-449-9444

Fax:

416-449-2658

Key Executives for Janssen Inc.

Janssen Inc. does not have any Key Executives recorded.

Janssen Inc. Key Developments

Ontario Institute for Cancer Research Extends Collaboration with Janssen Inc. to Develop Clinical Trials for Prostate Cancer

The Ontario Institute for Cancer Research (OICR) is extending its collaborative research partnership with Janssen Inc. to develop more multi-centre clinical trials and other translational research projects that address important clinical questions in prostate cancer. The new funds will be made available to qualifying researchers at cancer centres across Canada who are addressing important clinical questions in prostate cancer. The funding will be dispersed to researchers through the Canadian Cancer Clinical Trials Network, which is based at OICR, through an open application process.

Janssen Inc. in Collaboration with USAID to Expand Access to Multidrug-Resistant TB Therapy

Janssen Inc. signed a memorandum of understanding with the US Agency for International Development (USAID) regarding the firm's commitment to tackle multidrug-resistant tuberculosis (MDR-TB). Based on the terms of the agreement, Janssen will provide approximately 30,000 courses of its MDR-TB drug Sirturo (bedaquiline), which is worth an estimated USD 30 million, to USAID that consequently will work with national TB programmes to provide access to the treatment using certain eligibility criteria.

Janssen Inc. Announces Availability of PREZCOBIX(TM) for Canadians Living with HIV

Janssen Inc. announced that PREZCOBIX(TM) (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet. Patients with conditions like HIV that require either taking medication more than once a day or taking multiple medications may find it difficult to adhere to their treatment schedules. Research has shown that reducing the number of pills given to patients living with HIV can significantly improve adherence. PREZCOBIX(TM): A new option for the management of HIV PREZCOBIX(TM) is a fixed-dose combination tablet containing darunavir, a protease inhibitor currently marketed as PREZISTA(R), with a boosting agent called cobicistat, marketed as TYBOST(TM) by Gilead Sciences Inc. PREZCOBIX(TM) is approved in combination with other anti-retroviral agents for the treatment of HIV infection in treatment-naïve and treatment-experienced patients without darunavir resistance-associated mutations. PREZCOBIX(TM) received notice of compliance (NOC) from Health Canada on June 19, 2014.

Similar Private Companies By Industry

Company Name Region
Altima Dental Canada, Inc. Americas
Denning Management, Inc. Americas
High River Hospital And Nursing Home Americas
DTI Dental Technologies, Inc. Americas
HealthConnection.ca Ltd. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Janssen Inc., please visit www.janssen.ca. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.